Rafiye Ciftciler1, Seren Ozenirler2, Aysegul Atak Yucel3, Mustafa Cengiz4, Gulbanu Erkan5, Erkan Buyukdemirci6, Cemile Sönmez7, Guldal Yılmaz Esendaglı8. 1. Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey. 2. Department of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey. 3. Department of Immunology, Gazi University Faculty of Medicine, Ankara, Turkey. 4. Department of Gastroenterology, Ankara Oncology Education and Research Hospital, Ankara, Turkey. 5. Department of Gastroenterology, Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey. 6. Department of Public Health, Gazi University Faculty of Medicine, Ankara, Turkey. 7. Microbiology Specialist, Vaccine preventable Bacterial Diseases Research Laboratory, Public Health Institution of Turkey, Ankara, Turkey. 8. Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey.
Abstract
BACKGROUND: Liver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. METHODS: This study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. RESULTS: Serum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3±363.0 pg/mL vs 189.1±61.9 pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). CONCLUSIONS: Serum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.
BACKGROUND: Liver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis Bpatients. METHODS: This study included 120 patients with biopsy-proven hepatitis Bpatients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. RESULTS: Serum biglycan levels of chronic hepatitis Bpatients were found to be significantly higher than those of healthy controls (337.3±363.0 pg/mL vs 189.1±61.9 pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). CONCLUSIONS: Serum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.
Authors: C J Goddard; A Smith; J A Hoyland; P Baird; R F McMahon; A J Freemont; M Shomaf; N Y Haboubi; T W Warnes Journal: Gut Date: 1998-09 Impact factor: 23.059
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: C Wiberg; E Hedbom; A Khairullina; S R Lamandé; A Oldberg; R Timpl; M Mörgelin; D Heinegård Journal: J Biol Chem Date: 2001-03-19 Impact factor: 5.157
Authors: Diana J Leeming; Evrim Anadol; Robert Schierwagen; Morten A Karsdal; Inger Byrjalsen; Mette Juul Nielsen; Carolyn Schwarzer-Zander; Christoph Boesecke; Flemming Bendtsen; Søren Møller; Christian P Strassburg; Ulrich Spengler; Aleksander Krag; Jürgen Rockstroh; Jonel K Trebicka Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Chenghai Liu; Marianna D A Gaça; E Scott Swenson; Vincent F Vellucci; Michael Reiss; Rebecca G Wells Journal: J Biol Chem Date: 2003-01-22 Impact factor: 5.157
Authors: Mette J Nielsen; Sanne S Veidal; Morten A Karsdal; Diana J Ørsnes-Leeming; Ben Vainer; Stephen D Gardner; Robert Hamatake; Zachary D Goodman; Detlef Schuppan; Keyur Patel Journal: Liver Int Date: 2014-10-29 Impact factor: 5.828
Authors: Jenna M Mennella; Lori A Underhill; Sophia Collis; Geralyn M Lambert-Messerlian; Richard Tucker; Beatrice E Lechner Journal: Reprod Sci Date: 2020-08-17 Impact factor: 3.060